Research programme: therapeutic and diagnostic antibodies - Open Monoclonal Technology/Merck KGaAAlternative Names: Antibody discovery programme - OMT/Merck KGaA; Therapeutic and diagnostic OmniRat monoclonal antibodies - Open Monoclonal Technology/Merck KGaA
Latest Information Update: 21 Sep 2016
At a glance
- Originator Merck KGaA; Open Monoclonal Technology
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified